Document And Entity Information
Document And Entity Information - shares | 3 Months Ended | |
Mar. 31, 2019 | May 06, 2019 | |
Document Information [Line Items] | ||
Entity Registrant Name | PROTEON THERAPEUTICS INC | |
Entity Central Index Key | 0001359931 | |
Trading Symbol | prto | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Non-accelerated Filer | |
Entity Current Reporting Status | Yes | |
Entity Emerging Growth Company | true | |
Entity Ex Transition Period | false | |
Entity Small Business | true | |
Entity Common Stock, Shares Outstanding (in shares) | 19,585,394 | |
Document Type | 10-Q | |
Document Period End Date | Mar. 31, 2019 | |
Document Fiscal Year Focus | 2019 | |
Document Fiscal Period Focus | Q1 | |
Amendment Flag | false |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) | Mar. 31, 2019 | Dec. 31, 2018 |
Current assets: | ||
Cash and cash equivalents | $ 16,763,000 | $ 19,371,000 |
Available-for-sale investments | 2,496,000 | |
Prepaid expenses and other current assets | 1,035,000 | 1,369,000 |
Operating lease right-of-use asset | 135,000 | |
Total current assets | 17,933,000 | 23,236,000 |
Property and equipment, net | 105,000 | 263,000 |
Restricted cash | 22,000 | 22,000 |
Total assets | 18,060,000 | 23,521,000 |
Current liabilities: | ||
Accounts payable | 1,676,000 | 441,000 |
Accrued expenses | 1,559,000 | 2,637,000 |
Operating lease liability | 135,000 | |
Total current liabilities | 3,370,000 | 3,078,000 |
Total liabilities | 3,370,000 | 3,078,000 |
Commitments and contingencies (Note 5) | ||
Stockholders’ equity: | ||
Common stock, $0.001 par value, 100,000,000 shares authorized at March 31, 2019 and December 31, 2018; 19,585,394 and 19,243,651 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively | 19,000 | 19,000 |
Additional paid-in capital | 210,486,000 | 209,366,000 |
Accumulated deficit | (217,001,000) | (210,470,000) |
Accumulated other comprehensive income | 3,000 | 5,000 |
Total stockholders’ equity | 14,690,000 | 20,443,000 |
Total liabilities and stockholders’ equity | 18,060,000 | 23,521,000 |
Series A Convertible Preferred Stock [Member] | ||
Stockholders’ equity: | ||
Series A convertible preferred stock 22,000 shares authorized at March 31, 2019 and December 31, 2018 authorized; 21,660 and 22,000 issued and outstanding at March 31, 2019 and at December 31, 2018 , respectively | $ 21,183,000 | $ 21,523,000 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares | Mar. 31, 2019 | Dec. 31, 2018 |
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized (in shares) | 10,000,000 | 10,000,000 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized (in shares) | 100,000,000 | 100,000,000 |
Common stock, shares issued (in shares) | 19,585,394 | 19,243,651 |
Common stock, shares outstanding (in shares) | 19,585,394 | 19,243,651 |
Series A Convertible Preferred Stock [Member] | ||
Preferred stock, par value (in dollars per share) | $ 0.001 | |
Preferred stock, shares authorized (in shares) | 22,000 | 22,000 |
Preferred stock, shares issued (in shares) | 21,660 | 22,000 |
Preferred stock, shares outstanding (in shares) | 21,660 | 22,000 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Operating expenses: | ||
Research and development | $ 4,048 | $ 4,071 |
General and administrative | 2,589 | 2,294 |
Total operating expenses | 6,637 | 6,365 |
Loss from operations | (6,637) | (6,365) |
Other income : | ||
Investment income | 105 | 92 |
Other income, net | 1 | 192 |
Total other income | 106 | 284 |
Net loss | (6,531) | (6,081) |
Foreign currency translation adjustment | (2) | 2 |
Unrealized gain on available-for-sale investments | 8 | |
Comprehensive loss | (6,533) | (6,071) |
Reconciliation of net loss to net loss attributable to common stockholders: | ||
Net loss | (6,531) | (6,081) |
Net loss attributable to common stockholders | $ (6,531) | $ (6,081) |
Net loss per share attributable to common stockholders - basic and diluted (in dollars per share) | $ (0.34) | $ (0.34) |
Weighted-average common shares outstanding used in net loss per share attributable to common stockholders - basic and diluted (in shares) | 19,255,042 | 17,674,729 |
Included in operating expenses, above, are the following amounts for non-cash stock-based compensation expense: | ||
Allocated share-based compensation | $ 780 | $ 821 |
Research and Development Expense [Member] | ||
Included in operating expenses, above, are the following amounts for non-cash stock-based compensation expense: | ||
Allocated share-based compensation | 255 | 267 |
General and Administrative Expense [Member] | ||
Included in operating expenses, above, are the following amounts for non-cash stock-based compensation expense: | ||
Allocated share-based compensation | $ 525 | $ 554 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands | Preferred Stock [Member]Series A Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | AOCI Attributable to Parent [Member] | Total |
Balance (in shares) at Dec. 31, 2017 | 22,000 | 17,674,729 | ||||
Balance at Dec. 31, 2017 | $ 21,523 | $ 18 | $ 202,953 | $ (189,741) | $ (14) | $ 34,739 |
Stock-based compensation expense | 821 | 821 | ||||
Other comprehensive gain/(loss) | 10 | 10 | ||||
Net loss | (6,081) | (6,081) | ||||
Exercise of common stock options | ||||||
Issuance of common stock upon ESPP purchase | ||||||
Issuance of stock, net of issuance costs | ||||||
Balance (in shares) at Mar. 31, 2018 | 22,000 | 17,674,729 | ||||
Balance at Mar. 31, 2018 | $ 21,523 | $ 18 | 203,774 | (195,822) | (4) | 29,489 |
Balance (in shares) at Dec. 31, 2018 | 22,000 | 19,243,651 | ||||
Balance at Dec. 31, 2018 | $ 21,523 | $ 19 | 209,366 | (210,470) | 5 | 20,443 |
Conversion of Series A convertible preferred stock into Common Stock (in shares) | (340) | |||||
Conversion of Series A convertible preferred stock into Common Stock | $ (340) | |||||
Conversion of Series A convertible preferred stock into Common Stock (in shares) | 341,743 | |||||
Conversion of Series A convertible preferred stock into Common Stock | 340 | |||||
Stock-based compensation expense | 780 | 780 | ||||
Other comprehensive gain/(loss) | (2) | (2) | ||||
Net loss | (6,531) | (6,531) | ||||
Balance (in shares) at Mar. 31, 2019 | 21,660 | 19,585,394 | ||||
Balance at Mar. 31, 2019 | $ 21,183 | $ 19 | $ 210,486 | $ (217,001) | $ 3 | $ 14,690 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Operating activities | ||
Net loss | $ (6,531,000) | $ (6,081,000) |
Reconciliation of net loss to net cash used in operating activities: | ||
Depreciation | 174,000 | 32,000 |
Amortization of premium/discount on available-for-sale securities | (4,000) | 3,000 |
Foreign currency remeasurement loss | (136,000) | |
Stock-based compensation | 780,000 | 821,000 |
Changes in: | ||
Prepaid expenses and other assets | 349,000 | 121,000 |
Operating lease right-of-use asset | 65,000 | |
Interest receivable | (15,000) | 4,000 |
Accounts payable and accrued expenses | 155,000 | (220,000) |
Operating lease liability | (65,000) | |
Net cash used in operating activities | (5,092,000) | (5,456,000) |
Investing activities | ||
Proceeds from maturities of available-for-sale investments | 2,500,000 | 7,515,000 |
Proceeds from sale of available-for-sale investments | 1,999,000 | |
Purchase of property and equipment | (16,000) | (9,000) |
Net cash provided by investing activities | 2,484,000 | 9,505,000 |
Effect of exchange rate changes on cash | 137,000 | |
Decrease in cash, cash equivalents and restricted cash | (2,608,000) | 4,186,000 |
Cash, cash equivalents and restricted cash, beginning of period | 19,393,000 | 21,192,000 |
Cash, cash equivalents and restricted cash, end of period | $ 16,785,000 | $ 25,378,000 |
Note 1 - Organization and Opera
Note 1 - Organization and Operations | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Nature of Operations [Text Block] | 1. Organization and Operations The Company Proteon Therapeutics, Inc. (the “Company”) is a biopharmaceutical company that has historically focused on the development of novel, first June 2001 March 24, 2006. On June 22, 2017, 22,000 $0.001 $1,000 $22.0 August 2, 2017 ( 6 Pursuant to the Series A Financing, on August 2, 2017, August 3, 2017, 3 August 21, 2017. March 31, 2019, 340 341,743 Recent Developments On March 28, 2019, 2, 3 2 two • Fistula use for hemodialysis 69.7 65.1% p=0.328 not two 90 not 90 30 • Secondary patency not p=0.932 one 78% 76% Top-line results also included data relating to primary unassisted patency, one 2’s first 15% one p=0.178 not The proportions of patients experiencing adverse events were comparable between the vonapanitase and placebo arms of the study. The most common adverse events were consistent with medical events experienced by patients with CKD undergoing creation of a radiocephalic fistula and are summarized in the table below. Proportions of Patients Experiencing Common Adverse Events Vonapanitase Placebo Vascular Stenosis 35.1 % 41.7 % Fistula Thrombosis 16.8 % 18.6 % Local swelling 5.0 % 2.0 % Hematoma 5.0 % 3.9 % Note: Includes any adverse event that occurred in at least 5% Current Strategy Following the release of top-line data from the PATENCY- 2 March 28, 2019, not may not 10 third As of March 31, 2019, $16.8 2020. $217.0 March 31, 2019. one no |
Note 2 - Summary of Significant
Note 2 - Summary of Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | 2. Summary of Significant Accounting Policies Basis of Presentation, Principles of Consolidation and Use of Estimates The unaudited interim condensed consolidated financial statements of the Company included herein have been prepared, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements as of and for the year ended December 31, 2018 10 March 13, 2019. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company’s management, the accompanying unaudited interim condensed consolidated financial statements contain all adjustments which are necessary to fairly present the Company’s financial position as of March 31, 2019, three March 31, 2019 2018 three March 31, 2019 2018. three March 31, 2019 not December 31, 2019, The unaudited interim condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. These condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not may Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, available-for-sale investments, accounts payable, and accrued liabilities. The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. FASB ASC Topic 820, Fair Value Measurement and Disclosures not one three Level 1—Valuations Level 2—Valuations not Level 3—Valuations To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. Financial instruments measured at fair value on a recurring basis include cash equivalents and available-for-sale investments. There have been no three March 31, 2019 2018. no three March 31, 2019 2018. Net Income (Loss) per Share Attributable to Common Stockholders Basic net income (loss) per share is calculated by dividing net income (loss) attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing the net income attributable to common stockholders by the weighted-average number of common equivalent shares outstanding for the period, including any dilutive effect from outstanding stock options and warrants using the treasury stock method. The Company follows the two two two not Recent Accounting Pronouncements In May 2014, 2014 09, 2014 09” January 1, 2018, 2017 09 March 31, 2018. not In February 2016, 2016 02, 842 2016 02” 2016 01 January 1, 2019 not 842, 842. 842 842, not As a result of the adoption of ASU 2016 02, January 1, 2019, $0.2 8%, $0.2 no January 1, 2019. not 2016 02. In August 2016, 2016 15, 230 2016 15” eight December 15, 2017, first 2018 2016 15 March 31, 2018. not In November 2016, 2016 18, December 15, 2017, first 2018. 2016 18 March 31, 2018. $22,000 $22,000 three March 31, 2019 2018. In May 2017, No. 2017 09, 718 2017 09” 2017 09, not 2017 09 December 15, 2017. 2017 09 March 31, 2018. not In June 2018, No. 2018 07, 718 2018 07” 2018 07 2018 07 December 15, 2018. January 1, 2019. 2018 07 March 31, 2019. not March 31, 2018. |
Note 3 - Fair Value Measurement
Note 3 - Fair Value Measurements | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Fair Value Disclosures [Text Block] | 3. Fair Value Measurements Below is a summary of assets and liabilities measured at fair value (in thousands): As of March 31, 2019 Quoted Prices Significant Significant Total Assets Cash equivalents $ 15,378 $ - $ - $ 15,378 Total $ 15,378 $ - $ - $ 15,378 As of December 31, 2018 Quoted Prices Significant Significant Assets Cash equivalents $ 18,353 $ - $ - $ 18,353 Government securities 2,496 - - 2,496 Total $ 20,849 $ - $ - $ 20,849 As of March 31, 2019 December 31, 2018, 90 Available-for-sale securities at March 31, 2019 December 31, 2018 Amortized Cost Unrealized Gains Unrealized Losses Fair Value March 31, 2019 Government securities (Due within 1 year) $ - $ - $ - $ - $ - $ - $ - $ - December 31, 2018 Government securities (Due within 1 year) $ 2,496 $ - $ - $ 2,496 $ 2,496 $ - $ - $ 2,496 |
Note 4 - Property and Equipment
Note 4 - Property and Equipment, Net | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Property, Plant and Equipment Disclosure [Text Block] | 4. Property and Equipment, net Property and equipment, net consists of the following (in thousands): As of March 31, 2019 December 31, 2018 Computer equipment and software $ 227 $ 211 Furniture, fixtures, and other 365 365 Laboratory equipment 514 514 1,106 1,090 Accumulated depreciation (1,001 ) (827 ) Property and equipment, net $ 105 $ 263 Depreciation expense for the three March 31, 2019 2018 $0.2 $32,000, During the three March 31, 2019, March 31, 2019. $133,000 three March 31, 2019. |
Note 5 - Commitments and Contin
Note 5 - Commitments and Contingencies | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | 5. Commitments and Contingencies Operating Lease The Company’s primary facility is located in Waltham, Massachusetts, where it leases approximately 7,495 July 2018, September 2019. three March 31, 2019, $69,000, March 31, 2019, $135,000 $135,000 The weighted average remaining lease term and the weighted average discount rate for operating lease at March 31, 2019 Operating Lease Weighted average discount rate 8 % Weighted average remaining lease terms (years) 0.5 Future minimum payments required under operating leases as of March 31, 2019 Year Ending December 31: Amount 2019 138 Total minimum lease payments $ 138 In addition to the base rent, the Company is also responsible for its share of operating expenses and real estate taxes, in accordance with the terms of the lease agreement. As of March 31, 2019, $22,000 Restricted cash related to facilities leases As of March 31, 2019 December 31, 2018, $22,000 March 31, 2019 December 31, 2018, $22,000 |
Note 6 - Series A Preferred Fin
Note 6 - Series A Preferred Financing | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Preferred Stock [Text Block] | 6. Series A Preferred Financing On August 2, 2017, 22,000 $0.001 $1,000 $22.0 June 22, 2017. $0.5 1,005 $0.9949 13 1934, 9.985% Upon issuance, each share of Series A Preferred included an embedded beneficial conversion feature as the market price of the Company’s Common Stock on the date of issuance of the Series A Preferred was $1.30 $6.7 not The Company evaluated the Series A Preferred for liability or equity classification in accordance with the provisions of ASC 480, not not not not 480 no not As of March 31, 2019, 340 341,743 21,660 $0.001 March 31, 2019. |
Note 7 - Stock-based Compensati
Note 7 - Stock-based Compensation | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Share-based Payment Arrangement [Text Block] | 7. Stock-based Compensation Stock Options The following table summarizes stock option activity for employees: Options Weighted- Weighted- Aggregate Outstanding at December 31, 2018 4,597,226 $ 5.12 7.4 $ 404 Granted 1,182,500 $ 2.66 Exercised - Forfeited - Expired - Outstanding at March 31, 2019 5,779,726 $ 4.62 7.4 $ - Exercisable at March 31, 2019 2,606,279 $ 6.75 6.1 $ - Vested or expected to vest at March 31, 2019 (1) 5,779,726 $ 4.62 7.4 $ - __________________________ ( 1 Represents the number of vested options at March 31, 2019 March 31, 2019 Employee Stock Purchase Plan The 2014 140,500 January 1, January 1, 2015 January 1, 2024, one 281,000 January 1st. March 31, 2019, January 1, 2019 one December 31, 2018, 2014 192,436 ninth 2014 January 1, 2019 June 30, 2019. No three March 31, 2019 2018 2014 $50,900 $24,000 2014 three March 31, 2019 2018, Common Stock The Company has the following shares of Common Stock reserved for future issuance: March 31, December 31, 2019 2018 Conversion of Series A Preferred Stock 21,771,032 22,112,775 Stock-based compensation awards 6,818,214 5,163,957 Employee Stock Purchase Plan 118,120 118,120 Total 28,707,366 27,394,852 |
Note 8 - Income Taxes
Note 8 - Income Taxes | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | 8. Income Taxes Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The Company has evaluated the positive and negative evidence bearing upon the Company’s ability to realize the benefit of its deferred tax assets. Based on the Company’s history of operating losses, the Company has concluded that it is more likely than not not no three March 31, 2019 2018. |
Note 9 - Net Loss Per Share Att
Note 9 - Net Loss Per Share Attributable to Common Stockholders | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Earnings Per Share [Text Block] | 9. Net Loss per Share Attributable to Common Stockholders As described in Note 2, three March 31, 2019 2018 no two The following Common Stock equivalents, presented on an as converted basis, were excluded from the calculation of net loss per share for the periods presented, due to their anti-dilutive effect: Three Months Ended March 31, 2019 2018 Outstanding stock options 5,779,726 4,380,937 Outstanding ESPP shares 267,242 55,716 Convertible preferred stock 21,771,032 22,112,775 27,818,000 26,549,428 |
Note 10 - Subsequent Events
Note 10 - Subsequent Events | 3 Months Ended |
Mar. 31, 2019 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | 10. Subsequent Events Following the release of top-line data from the PATENCY- 2 April 15, 2019, As a result of these strategic alternatives and in connection with the Company’s discontinuation of research and development activities, the Company has terminated or expects to terminate all but four May 2019.In 2019, $3.0 $3.2 |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2019 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Basis of Presentation, Principles of Consolidation and Use of Estimates The unaudited interim condensed consolidated financial statements of the Company included herein have been prepared, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements as of and for the year ended December 31, 2018 10 March 13, 2019. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company’s management, the accompanying unaudited interim condensed consolidated financial statements contain all adjustments which are necessary to fairly present the Company’s financial position as of March 31, 2019, three March 31, 2019 2018 three March 31, 2019 2018. three March 31, 2019 not December 31, 2019, The unaudited interim condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. These condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not may |
Derivatives, Policy [Policy Text Block] | Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, available-for-sale investments, accounts payable, and accrued liabilities. The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. FASB ASC Topic 820, Fair Value Measurement and Disclosures not one three Level 1—Valuations Level 2—Valuations not Level 3—Valuations To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. Financial instruments measured at fair value on a recurring basis include cash equivalents and available-for-sale investments. There have been no three March 31, 2019 2018. no three March 31, 2019 2018. |
Earnings Per Share, Policy [Policy Text Block] | Net Income (Loss) per Share Attributable to Common Stockholders Basic net income (loss) per share is calculated by dividing net income (loss) attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing the net income attributable to common stockholders by the weighted-average number of common equivalent shares outstanding for the period, including any dilutive effect from outstanding stock options and warrants using the treasury stock method. The Company follows the two two two not |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent Accounting Pronouncements In May 2014, 2014 09, 2014 09” January 1, 2018, 2017 09 March 31, 2018. not In February 2016, 2016 02, 842 2016 02” 2016 01 January 1, 2019 not 842, 842. 842 842, not As a result of the adoption of ASU 2016 02, January 1, 2019, $0.2 8%, $0.2 no January 1, 2019. not 2016 02. In August 2016, 2016 15, 230 2016 15” eight December 15, 2017, first 2018 2016 15 March 31, 2018. not In November 2016, 2016 18, December 15, 2017, first 2018. 2016 18 March 31, 2018. $22,000 $22,000 three March 31, 2019 2018. In May 2017, No. 2017 09, 718 2017 09” 2017 09, not 2017 09 December 15, 2017. 2017 09 March 31, 2018. not In June 2018, No. 2018 07, 718 2018 07” 2018 07 2018 07 December 15, 2018. January 1, 2019. 2018 07 March 31, 2019. not March 31, 2018. |
Note 1 - Organization and Ope_2
Note 1 - Organization and Operations (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Notes Tables | |
Proportions of Patients Experiencing Adverse Events [Table Text Block] | Vonapanitase Placebo Vascular Stenosis 35.1 % 41.7 % Fistula Thrombosis 16.8 % 18.6 % Local swelling 5.0 % 2.0 % Hematoma 5.0 % 3.9 % |
Note 3 - Fair Value Measureme_2
Note 3 - Fair Value Measurements (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Notes Tables | |
Fair Value, Assets Measured on Recurring Basis [Table Text Block] | As of March 31, 2019 Quoted Prices Significant Significant Total Assets Cash equivalents $ 15,378 $ - $ - $ 15,378 Total $ 15,378 $ - $ - $ 15,378 As of December 31, 2018 Quoted Prices Significant Significant Assets Cash equivalents $ 18,353 $ - $ - $ 18,353 Government securities 2,496 - - 2,496 Total $ 20,849 $ - $ - $ 20,849 |
Available-for-sale Securities [Table Text Block] | Amortized Cost Unrealized Gains Unrealized Losses Fair Value March 31, 2019 Government securities (Due within 1 year) $ - $ - $ - $ - $ - $ - $ - $ - December 31, 2018 Government securities (Due within 1 year) $ 2,496 $ - $ - $ 2,496 $ 2,496 $ - $ - $ 2,496 |
Note 4 - Property and Equipme_2
Note 4 - Property and Equipment, Net (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Notes Tables | |
Property, Plant and Equipment [Table Text Block] | As of March 31, 2019 December 31, 2018 Computer equipment and software $ 227 $ 211 Furniture, fixtures, and other 365 365 Laboratory equipment 514 514 1,106 1,090 Accumulated depreciation (1,001 ) (827 ) Property and equipment, net $ 105 $ 263 |
Note 5 - Commitments and Cont_2
Note 5 - Commitments and Contingencies (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Notes Tables | |
Lease, Cost [Table Text Block] | Operating Lease Weighted average discount rate 8 % Weighted average remaining lease terms (years) 0.5 |
Lessee, Operating Lease, Liability, Maturity [Table Text Block] | Year Ending December 31: Amount 2019 138 Total minimum lease payments $ 138 |
Note 7 - Stock-based Compensa_2
Note 7 - Stock-based Compensation (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Notes Tables | |
Share-based Payment Arrangement, Option, Activity [Table Text Block] | Options Weighted- Weighted- Aggregate Outstanding at December 31, 2018 4,597,226 $ 5.12 7.4 $ 404 Granted 1,182,500 $ 2.66 Exercised - Forfeited - Expired - Outstanding at March 31, 2019 5,779,726 $ 4.62 7.4 $ - Exercisable at March 31, 2019 2,606,279 $ 6.75 6.1 $ - Vested or expected to vest at March 31, 2019 (1) 5,779,726 $ 4.62 7.4 $ - |
Common Stock Reserved for Future Issuance [Table Text Block] | <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,</td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td> <td> </td> <td colspan="3" style="white-space: nowrap; text-align: center"> </td> <td> </td> <td colspan="3" style="white-space: nowrap; text-align: center"> </td> </tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 70%; text-align: left">Conversion of Series A Preferred Stock</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,771,032</div></td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22,112,775</div></td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">Stock-based compensation awards</td> <td style="color: red"> </td> <td style="color: red; text-align: left"> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,818,214</div></td> <td style="white-space: nowrap; color: red; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,163,957</div></td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left; padding-bottom: 1pt">Employee Stock Purchase Plan</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">118,120</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">118,120</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.25pt">Total</td> <td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left"> </td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">28,707,366</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left"> </td> <td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left"> </td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">27,394,852</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left"> </td> </tr> </table></div>" id="sjs-B5"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,</td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td> <td> </td> <td colspan="3" style="white-space: nowrap; text-align: center"> </td> <td> </td> <td colspan="3" style="white-space: nowrap; text-align: center"> </td> </tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 70%; text-align: left">Conversion of Series A Preferred Stock</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,771,032</div></td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22,112,775</div></td> <td style="white-space: nowrap; width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left">Stock-based compensation awards</td> <td style="color: red"> </td> <td style="color: red; text-align: left"> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,818,214</div></td> <td style="white-space: nowrap; color: red; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,163,957</div></td> <td style="white-space: nowrap; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: left; padding-bottom: 1pt">Employee Stock Purchase Plan</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">118,120</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">118,120</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.25pt">Total</td> <td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left"> </td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">28,707,366</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left"> </td> <td style="padding-bottom: 2.25pt"> </td> <td style="border-bottom: Black 2.25pt double; text-align: left"> </td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">27,394,852</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left"> </td> </tr> </table></div> |
Note 9 - Net Loss Per Share A_2
Note 9 - Net Loss Per Share Attributable to Common Stockholders (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Notes Tables | |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | Three Months Ended March 31, 2019 2018 Outstanding stock options 5,779,726 4,380,937 Outstanding ESPP shares 267,242 55,716 Convertible preferred stock 21,771,032 22,112,775 27,818,000 26,549,428 |
Note 1 - Organization and Ope_3
Note 1 - Organization and Operations (Details Textual) - USD ($) $ / shares in Units, $ in Thousands | Aug. 02, 2017 | Mar. 31, 2019 | Dec. 31, 2018 |
Preferred Stock, Par or Stated Value Per Share | $ 0.001 | $ 0.001 | |
Cash, Cash Equivalents, and Short-term Investments, Total | $ 16,800 | ||
Retained Earnings (Accumulated Deficit), Ending Balance | $ (217,001) | $ (210,470) | |
Common Stock [Member] | |||
Stock Issued During Period, Shares, Conversion of Convertible Securities | 341,743 | ||
Series A Convertible Preferred Stock [Member] | |||
Stock Issued During Period, Shares, New Issues | 22,000 | ||
Preferred Stock, Par or Stated Value Per Share | $ 0.001 | $ 0.001 | |
Shares Issued, Price Per Share | $ 1,000 | ||
Proceeds from Issuance of Convertible Preferred Stock | $ 22,000 | ||
Conversion of Stock, Shares Converted | 340 |
Note 1 - Organization and Ope_4
Note 1 - Organization and Operations - Proportions of Patients (Details) | 3 Months Ended |
Mar. 31, 2019 | |
Vascular Stenosis [Member] | Vonapanitase [Member] | |
Patients experiencing common adverse events | 35.10% |
Vascular Stenosis [Member] | Placebo [Member] | |
Patients experiencing common adverse events | 41.70% |
Fistula Thrombosis [Member] | Vonapanitase [Member] | |
Patients experiencing common adverse events | 16.80% |
Fistula Thrombosis [Member] | Placebo [Member] | |
Patients experiencing common adverse events | 18.60% |
Local Swelling [Member] | Vonapanitase [Member] | |
Patients experiencing common adverse events | 5.00% |
Local Swelling [Member] | Placebo [Member] | |
Patients experiencing common adverse events | 2.00% |
Hemotoma [Member] | Vonapanitase [Member] | |
Patients experiencing common adverse events | 5.00% |
Hemotoma [Member] | Placebo [Member] | |
Patients experiencing common adverse events | 3.90% |
Note 2 - Summary of Significa_2
Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) | 3 Months Ended | |||
Mar. 31, 2019 | Mar. 31, 2018 | Jan. 01, 2019 | Dec. 31, 2018 | |
Operating Lease, Liability, Current | $ 135,000 | |||
Operating Lease, Weighted Average Discount Rate, Percent | 8.00% | |||
Operating Lease, Right-of-Use Asset | $ 135,000 | |||
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Total | (2,608,000) | $ 4,186,000 | ||
Restricted Cash and Cash Equivalents, Total | 22,000 | 22,000 | ||
Accounting Standards Update 2016-02 [Member] | ||||
Operating Lease, Liability, Current | $ 200,000 | |||
Operating Lease, Weighted Average Discount Rate, Percent | 8.00% | |||
Operating Lease, Right-of-Use Asset | $ 200,000 | |||
Accounting Standards Update 2016-18 [Member] | ||||
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Total | $ 22,000 | $ 22,000 |
Note 3 - Fair Value Measureme_3
Note 3 - Fair Value Measurements - Summary of Assets and Liabilities Measured at Fair Value (Details) - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
Total | $ 15,378 | $ 20,849 |
Cash Equivalents [Member] | ||
Cash equivalents | 15,378 | 18,353 |
US Government Agencies Debt Securities [Member] | ||
Government securities | 2,496 | |
Fair Value, Inputs, Level 1 [Member] | ||
Total | 15,378 | 20,849 |
Fair Value, Inputs, Level 1 [Member] | Cash Equivalents [Member] | ||
Cash equivalents | 15,378 | 18,353 |
Fair Value, Inputs, Level 1 [Member] | US Government Agencies Debt Securities [Member] | ||
Government securities | 2,496 | |
Fair Value, Inputs, Level 2 [Member] | ||
Total | ||
Fair Value, Inputs, Level 2 [Member] | Cash Equivalents [Member] | ||
Cash equivalents | ||
Fair Value, Inputs, Level 2 [Member] | US Government Agencies Debt Securities [Member] | ||
Government securities | ||
Fair Value, Inputs, Level 3 [Member] | ||
Total | ||
Fair Value, Inputs, Level 3 [Member] | Cash Equivalents [Member] | ||
Cash equivalents | ||
Fair Value, Inputs, Level 3 [Member] | US Government Agencies Debt Securities [Member] | ||
Government securities |
Note 3 - Fair Value Measureme_4
Note 3 - Fair Value Measurements - Available-for-sale Securities (Details) - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
Amortized Cost | $ 2,496 | |
Unrealized Gains | ||
Unrealized Losses | ||
Fair Value | 2,496 | |
US Government Agencies Debt Securities [Member] | ||
Amortized Cost | 2,496 | |
Unrealized Gains | ||
Unrealized Losses | ||
Fair Value | $ 2,496 |
Note 4 - Property and Equipme_3
Note 4 - Property and Equipment, Net (Details Textual) - USD ($) | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Depreciation, Total | $ 174,000 | $ 32,000 |
Laboratory Equipment [Member] | Research and Development Expense [Member] | ||
Impairment of Long-Lived Assets Held-for-use | $ 133,000 |
Note 4 - Property and Equipme_4
Note 4 - Property and Equipment, Net - Summary of Property and Equipment (Details) - USD ($) $ in Thousands | Mar. 31, 2019 | Dec. 31, 2018 |
Property and equipment | $ 1,106 | $ 1,090 |
Accumulated depreciation | (1,001) | (827) |
Property and equipment, net | 105 | 263 |
Computer Equipment and Software [Member] | ||
Property and equipment | 227 | 211 |
Furniture and Fixtures [Member] | ||
Property and equipment | 365 | 365 |
Laboratory Equipment [Member] | ||
Property and equipment | $ 514 | $ 514 |
Note 5 - Commitments and Cont_3
Note 5 - Commitments and Contingencies (Details Textual) | 3 Months Ended | |
Mar. 31, 2019USD ($)ft² | Dec. 31, 2018USD ($) | |
Area of Real Estate Property | ft² | 7,495 | |
Operating Lease, Expense | $ 69,000 | |
Operating Lease, Right-of-Use Asset | 135,000 | |
Operating Lease, Liability, Current | 135,000 | |
Security Deposit | 22,000 | |
Letters of Credit Outstanding, Amount | 22,000 | 22,000 |
Loans Pledged as Collateral | $ 22,000 | $ 22,000 |
Note 5 - Commitments and Cont_4
Note 5 - Commitments and Contingencies - Operating Leases (Details) | Mar. 31, 2019 |
Weighted average discount rate | 8.00% |
Weighted average remaining lease terms (years) (Year) | 182 days |
Note 5 - Commitments and Cont_5
Note 5 - Commitments and Contingencies - Future Minimum Payments for Operating Leases (Details) $ in Thousands | Mar. 31, 2019USD ($) |
2019 | $ 138 |
Note 6 - Series A Preferred F_2
Note 6 - Series A Preferred Financing (Details Textual) - USD ($) $ / shares in Units, $ in Millions | Aug. 02, 2017 | Mar. 31, 2019 | Dec. 31, 2018 |
Preferred Stock, Par or Stated Value Per Share | $ 0.001 | $ 0.001 | |
Common Stock [Member] | |||
Stock Issued During Period, Shares, Conversion of Convertible Securities | 341,743 | ||
Series A Convertible Preferred Stock [Member] | |||
Stock Issued During Period, Shares, New Issues | 22,000 | ||
Preferred Stock, Par or Stated Value Per Share | $ 0.001 | $ 0.001 | |
Shares Issued, Price Per Share | $ 1,000 | ||
Proceeds from Issuance of Convertible Preferred Stock | $ 22 | ||
Payments of Stock Issuance Costs | $ 0.5 | ||
Convertible Preferred Stock, Shares Issued upon Conversion | 1,005 | ||
Convertible Preferred Stock, Conversion Price of Shares Issued upon Conversion | $ 0.9949 | ||
Convertible Preferred Stock, Maximum Ownership Percentage Allowed after Conversion of Stock | 9.985% | ||
Preferred Stock, Redemption Price Per Share | $ 1.30 | ||
Accretion of Redeemable Convertible Preferred Stock to Redemption Value | $ 6.7 | ||
Conversion of Stock, Shares Converted | 340 | ||
Preferred Stock, Shares Issued, Total | 21,660 | 22,000 | |
Preferred Stock, Shares Outstanding, Ending Balance | 21,660 | 22,000 |
Note 7 - Stock-based Compensa_3
Note 7 - Stock-based Compensation (Details Textual) - USD ($) | Jan. 01, 2019 | Jan. 01, 2018 | Mar. 31, 2019 | Mar. 31, 2018 | Dec. 31, 2018 | Dec. 31, 2014 |
Share-based Payment Arrangement, Expense | $ 780,000 | $ 821,000 | ||||
The 2014 Employee Stock Purchase Plan [Member] | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | 192,436 | 140,500 | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Annual Additional Shares, Percentage | 1.00% | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Additional Shares Authorizable | 281,000 | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized | 1 | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period | 0 | 0 | ||||
Share-based Payment Arrangement, Expense | $ 50,900 | $ 24,000 |
Note 7 - Stock-based Compensa_4
Note 7 - Stock-based Compensation - Stock Option Activity for Employees and Non-employees (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2019 | Dec. 31, 2018 | ||
Options Outstanding, Beginning Balance (in shares) | 4,597,226 | ||
Options Outstanding, Weighted Average Exercise Price, Beginning Balance (in dollars per share) | $ 5.12 | ||
Options Outstanding, Weighted-average Remaining Contractual Term (Year) | 7 years 146 days | 7 years 146 days | |
Options Outstanding, Aggregate Intrinsic Value | $ 404 | ||
Options Granted (in shares) | 1,182,500 | ||
Options Granted, Weighted Average Exercise Price (in dollars per share) | $ 2.66 | ||
Options Exercised (in shares) | |||
Options Exercised, Weighted Average Exercise Price (in dollars per share) | |||
Options Forfeited (in shares) | |||
Options Forfeited, Weighted Average Exercise Price (in dollars per share) | |||
Options Expired (in shares) | |||
Options Expired, Weighted Average Exercise Price (in dollars per share) | |||
Options Outstanding, Ending Balance (in shares) | 5,779,726 | 4,597,226 | |
Options Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share) | $ 4.62 | $ 5.12 | |
Options Exercisable (in shares) | 2,606,279 | ||
Options Exercisable, Weighted Average Exercise Price (in dollars per share) | $ 6.75 | ||
Options Exercisable, Weighted-average Remaining Contractual Term (Year) | 6 years 36 days | ||
Options Exercisable, Aggregate Intrinsic Value | |||
Options Vested or Expected to Vest (in shares) | [1] | 5,779,726 | |
Options Vested or Expected to Vest, Weighted Average Exercise Price (in dollars per share) | [1] | $ 4.62 | |
Options Vested or Expected to Vest, Weighted-average Remaining Contractual Term (Year) | [1] | 7 years 146 days | |
Options Vested or Expected to Vest, Aggregate Intrinsic Value | [1] | ||
[1] | Represents the number of vested options at March 31, 2019 plus the number of unvested options expected to vest based on the unvested options outstanding at March 31, 2019 |
Note 7 - Stock-based Compensa_5
Note 7 - Stock-based Compensation - Common Stock Reserved for Future Issuance (Details) - shares | Mar. 31, 2019 | Dec. 31, 2018 |
Reserved for future issuance (in shares) | 28,707,366 | 27,394,852 |
The 2014 Employee Stock Purchase Plan [Member] | ||
Reserved for future issuance (in shares) | 118,120 | 118,120 |
Performance Shares [Member] | ||
Reserved for future issuance (in shares) | 6,818,214 | 5,163,957 |
Conversion of Series A Preferred Stock to Common Stock [Member] | ||
Reserved for future issuance (in shares) | 21,771,032 | 22,112,775 |
Note 8 - Income Taxes (Details
Note 8 - Income Taxes (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Income Tax Expense (Benefit), Total | $ 0 | $ 0 |
Note 9 - Net Loss Per Share A_3
Note 9 - Net Loss Per Share Attributable to Common Stockholders - Common Stock Equivalents Excluded From Calculation of Net Loss Per Share (Details) - shares | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Antidilutive Securities (in shares) | 27,818,000 | 26,549,428 |
Convertible Preferred Stock [Member] | ||
Antidilutive Securities (in shares) | 21,771,032 | 22,112,775 |
Share-based Payment Arrangement, Option [Member] | ||
Antidilutive Securities (in shares) | 5,779,726 | 4,380,937 |
Employee Stock Purchase Plan [Member] | ||
Antidilutive Securities (in shares) | 267,242 | 55,716 |
Note 10 - Subsequent Events (De
Note 10 - Subsequent Events (Details Textual) - Subsequent Event [Member] $ in Millions | Apr. 15, 2019USD ($) |
Minimum [Member] | |
Restructuring and Related Cost, Expected Cost, Total | $ 3 |
Maximum [Member] | |
Restructuring and Related Cost, Expected Cost, Total | $ 3.2 |